BD
BD is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at BD.
BD is a company.
Key people at BD.
BD (Becton, Dickinson and Company) is a leading global medical technology company that manufactures and sells medical devices, instrument systems, reagents, and provides consulting and analytics services, advancing healthcare through improved medical discovery, diagnostics, and care delivery.[5][6][7][8] It operates primarily in three segments—BD Medical (including Medication Delivery Solutions, Medication Management Solutions, Pharmaceutical Systems, and Advanced Patient Monitoring), with products serving hospitals, labs, clinics, physicians, and pharmaceutical companies worldwide, generating revenue from technologies that address infections, medication management, and diagnostics.[3][4][5] In fiscal 2025, BD reported 3.9% organic revenue growth in its core "New BD" business post-upcoming divestitures, adjusted EPS growth of 9.6% to $14.40, and margin expansion driven by operational efficiencies, while maintaining strong free cash flow margins of 12.9% over five years and a safe 3.0x net-debt-to-EBITDA ratio.[3][4]
BD touches 90% of hospital patients annually through its products and invests heavily in R&D, with global manufacturing across North America, Europe, and Asia, positioning it as a Fortune 500 company (#211 in 2024) with resilient growth amid healthcare challenges.[2][3][5][6]
Founded over 125 years ago, BD (Becton, Dickinson and Company) has evolved from early medical device innovations into a multinational powerhouse in medtech.[6][8] Key historical milestones include the 2014 acquisition of CareFusion for $12.2 billion, expanding its medication management capabilities; the 2017 acquisition of C.R. Bard, rebranded under BD and bolstering vascular, urology, and oncology portfolios; and the 2024 purchase of Edwards Lifesciences' critical care unit for $4.2 billion, forming the Advanced Patient Monitoring business.[5]
The company's idea emerged from foundational healthcare needs, with early traction in syringes and diagnostics, leading to pivotal moments like these acquisitions that scaled its global reach to serve hundreds of countries and produce billions of devices annually.[6][7][8] Leadership under Chairman, CEO, and President Tom Polen has emphasized execution, as seen in fiscal 2025 results amid a transformative spin-off of its Biosciences and Diagnostic Solutions businesses.[4]
BD rides megatrends in medtech like aging populations, infection control, and precision diagnostics, amplified by post-pandemic healthcare digitization and supply chain resilience needs.[3][6][8] Timing is favorable amid value-unlocking deals like the Waters spin-off, which removes growth overhangs and funds $4B cash infusion, aligning with market forces favoring recession-resilient firms with absolute value in frothy markets.[2][4]
As a scale player influencing the ecosystem through acquisitions, R&D, and global supply (billions of devices yearly), BD shapes standards in medication management and monitoring, enabling providers to tackle infections and care delivery—though execution risks in M&A integration and new product development persist.[2][3][5]
BD's trajectory hinges on executing the Q1 2026 Waters spin-off, unlocking value in "New BD" at attractive valuations (<10x FY26 earnings) while sustaining 3-5% organic growth via franchises like PureWick™ and oncology tools.[2][4] Trends like AI-driven diagnostics, outpatient shifts, and volume-based pricing in regions like China will shape it, with strengths in cash generation supporting buybacks, R&D, and bolt-ons despite debt from deals.[2][3][4]
Influence may evolve toward a leaner medtech pure-play, prioritizing margins (targeted 25%+ adjusted operating) and downside protection, potentially delivering superior returns if catalysts like growth normalization materialize—cementing its role from good to great in advancing global health.[1][2][6]
Key people at BD.
